v3.26.1
Segments and Related Information (Tables)
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Company's Operating Segments
Financial information, including revenue and expenses, with respect to the Company’s operating segments, is as follows (in millions):

Year Ended December 31, 2025
InfrastructureLife SciencesSpectrumNon-Operating CorporateOther and EliminationsINNOVATE
Revenue$1,210.3 $12.5 $23.2 $— $— $1,246.0 
Cost of revenue1,026.2 8.4 11.7 — — 1,046.3 
Selling, general and administrative expenses
115.2 14.6 7.6 15.6 0.1 153.1 
Depreciation and amortization12.1 0.4 5.0 — — 17.5 
Other operating loss (income) (1)
1.4 — (1.0)— — 0.4 
Income (loss) from operations$55.4 $(10.9)$(0.1)$(15.6)$(0.1)$28.7 
Other data:
Capital cash expenditures
$23.4 $— $2.7 $— $— $26.1 
(1) Other operating loss for the year ended December 31, 2025, primarily consisted of a loss on lease modification and losses on the sales of various properties at the Company's Infrastructure segment, partially offset primarily by a gain on legal settlement at the Company's Spectrum Segment.
Year Ended December 31, 2024
InfrastructureLife SciencesSpectrumNon-Operating CorporateOther and EliminationsINNOVATE
Revenue$1,071.6 $9.8 $25.7 $— $— $1,107.1 
Cost of revenue880.4 6.4 11.5 — — 898.3 
Selling, general and administrative expenses123.1 17.1 7.3 12.7 — 160.2 
Depreciation and amortization12.0 0.4 5.1 0.1 — 17.6 
Other operating (income) loss (1)
(9.6)— 0.4 0.2 — (9.0)
Income (loss) from operations
$65.7 $(14.1)$1.4 $(13.0)$— $40.0 
Other data:
Capital cash expenditures
$17.6 $— $1.4 $— $— $19.0 
(1) Other operating income at the Company's Infrastructure segment for the year ended December 31, 2024, related mainly to a gain on a lease modification and a net gain on the sale and disposal of various properties.

Certain balance sheet data:
December 31, 2025
InfrastructureLife SciencesSpectrumNon-Operating CorporateOther and EliminationsINNOVATE
Investments (1)
$— $1.8 $— $— $— $1.8 
Total assets
$758.9 $9.6 $174.5 $7.1 $— $950.1 
December 31, 2024
InfrastructureLife SciencesSpectrumNon-Operating CorporateOther and EliminationsINNOVATE
Investments (1)
$— $1.8 $— $1.8 $— $3.6 
Total assets
$683.6 $11.9 $178.9 $16.7 $— $891.1 
(1) The Company's equity method investments in its Life Sciences segment totaled $0.9 million as of both December 31, 2025 and 2024.

 Year Ended December 31,
20252024
Reconciliation of the consolidated segment income from operations to consolidated loss from operations before income taxes:
Income from operations$28.7 $40.0 
Interest expense(89.0)(74.5)
Loss from equity investees(5.9)(2.3)
Other income, net4.7 3.4 
Loss from operations before income taxes$(61.5)$(33.4)